作者：
Amberg, Alexander [1]
;
Anger, Lennart T. [2]
;
Bercu, Joel [3]
;
Bower, David [4]
;
Cross, Kevin P. [5]
;
Custer, Laura [6]
;
Harvey, James S. [7]
;
Hasselgren, Catrin [8]
;
Honma, Masamitsu [9]
;
Johnson, Candice [10]
;
Jolly, Robert [11]
;
Kenyon, Michelle O. [12]
;
Kruhlak, Naomi L. [13]
;
Leavitt, Penny ;
Quigley, Donald P. ;
Miller, Scott ;
Snodin, David ;
Stavitskaya, Lidiya ;
Teasdale, Andrew ;
Trejo-Martin, Alejandra ;
White, Angela T. ;
Wichard, Joerg ;
Myatt, Glenn J.
作者单位：
Natl Inst Hlth Sci, Div Genet & Mutagenesis, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan
[1]
Leadscope Inc, 1393 Dublin Rd, Columbus, OH 43215 USA
[2]
US FDA, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
[3]
GlaxoSmithKline Preclin Dev, Pk Rd, Ware SG12 0DP, Herts, England
[4]
AstraZeneca, Pharmaceut Technol & Dev, Charter Way,Silk Rd Business Pk, Macclesfield SK10 2NX
[5]
Pfizer Worldwide Res & Dev, Drug Safety, Genet Toxicol, Eastern Point Rd, Groton, CT 06340 USA
[6]
Bayer AG, Div Pharmaceut, Invest Toxicol, Muellerstr 178, D-13353 Berlin, Germany
[7]
Sanofi, R&D Preclin Safety Frankfurt, Ind Pk Hochst, D-65926 Frankfurt, Germany
[8]
Bristol Myers Squibb, Drug Safety Evaluat, 1 Squibb Dr, New Brunswick, NJ 08903 USA
[9]
Gilead Sci, Nonclin Safety & Pathobiol, 333 Lakeside Dr, Foster City, CA 94404 USA
[10]
Xiphora Biopharma Consulting, 9 Richmond Apartments,Redland Court Rd, Bristol BS6 7BG, Avon, England
[11]
Genentech Inc, Safety Assessment, 1 DNA Way, San Francisco, CA 94080 USA
[12]
Eli Lilly & Co, Div Toxicol, Indianapolis, IN 46285 USA
[13]
发布时间
2020-05-08
换一批
